|
1
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu R, Lv QL, Yu J, Hu L, Zhang LH, Cheng
Y and Zhou HH: Correlating transcriptional networks with
pathological complete response following neoadjuvant chemotherapy
for breast cancer. Breast Cancer Res Treat. 151:607–618. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yuan JQ, Wang SM, Tang LL, Mao J, Wu YH,
Hai J, Luo SY, Ou HY, Guo L, Liao LQ, et al: Relative dose
intensity and therapy efficacy in different breast cancer molecular
subtypes: A retrospective study of early stage breast cancer
patients treated with neoadjuvant chemotherapy. Breast Cancer Res
Treat. 151:405–413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oualla K, El-Zawahry HM, Arun B, Reuben
JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT and Fouad
TM: Novel therapeutic strategies in the treatment of
triple-negative breast cancer. Ther Adv Med Oncol. 9:493–511. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liao L, Song M, Li X, Tang L, Zhang T,
Zhang L, Pan Y, Chouchane L and Ma X: E3 ubiquitin ligase UBR5
drives the growth and metastasis of triple-negative breast cancer.
Cancer Res. 77:2090–2101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Insel PA: Seminars in medicine of the Beth
Israel Hospital, Boston. Adrenergic receptors-evolving concepts and
clinical implications. N Engl J Med. 334:580–585. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cole SW and Sood AK: Molecular pathways:
Beta-adrenergic signaling in cancer. Clin Cancer Res. 18:1201–1206.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He RH, He YJ, Tang YJ, Zhou HH, McLeod HL
and Liu J: The potential anticancer effect of beta-blockers and the
genetic variations involved in the interindividual difference.
Pharmacogenomics. 17:74–79. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schuller HM: Beta-adrenergic signaling, a
novel target for cancer therapy? Oncotarget. 1:466–469.
2010.PubMed/NCBI
|
|
11
|
Powe DG, Voss MJ, Zänker KS, Habashy HO,
Green AR, Ellis IO and Entschladen F: Beta-blocker drug therapy
reduces secondary cancer formation in breast cancer and improves
cancer specific survival. Oncotarget. 1:628–638. 2010.PubMed/NCBI
|
|
12
|
Melhem-Bertrandt A, Chavez-Macgregor M,
Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD,
Hortobagyi GN and Gonzalez-Angulo AM: Beta-blocker use is
associated with improved relapse-free survival in patients with
triple-negative breast cancer. J Clin Oncol. 29:2645–2652. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barron TI, Connolly RM, Sharp L, Bennett K
and Visvanathan K: Beta blockers and breast cancer mortality: A
population based study. J Clin Oncol. 29:2635–2644. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Khan MG: Cardia Drug Therapy. Humana Press
Inc; Totowa, New Jersey: 2007
|
|
15
|
James PA, Oparil S, Carter BL, Cushman WC,
Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML,
MacKenzie TD, Ogedegbe O, et al: 2014 evidence-based guideline for
the management of high blood pressure in adults: Report from the
panel members appointed to the Eighth Joint National Committee.
JAMA. 311:pp. 507–520. 2014, View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Léauté-Labrèze C, Dumas de la Roque E,
Hubiche T, Boralevi F, Thambo JB and Taïeb A: Propranolol for
severe hemangiomas of infancy. N Engl J Med. 358:2649–2651. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Montoya A, Amaya CN, Belmont A, Diab N,
Trevino R, Villanueva G, Rains S, Sanchez LA, Badri N, Otoukesh S,
et al: Use of non-selective β-blockers is associated with decreased
tumor proliferative indices in early stage breast cancer.
Oncotarget. 8:6446–6460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pasquier E, Ciccolini J, Carre M,
Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C,
Kavallaris M and André N: Propranolol potentiates the
anti-angiogenic effects and antitumor efficacy of chemotherapy
agents: Implication in breast cancer treatment. Oncotarget.
2:797–809. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang D, Ma QY, Hu HT and Zhang M:
β2-adrenergic antagonists suppress pancreatic cancer
cell invasion by inhibiting CREB, NFκB and AP-1. Cancer Biol Ther.
10:19–29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hassan S, Karpova Y, Baiz D, Yancey D,
Pullikuth A, Flores A, Register T, Cline JM, D'Agostino R Jr,
Danial N, et al: Behavioral stress accelerates prostate cancer
development in mice. J Clin Invest. 123:874–886. 2013.PubMed/NCBI
|
|
21
|
Diaz ES, Karlan BY and Li AJ: Impact of
beta blockers on epithelial ovarian cancer survival. Gynecol Oncol.
127:375–378. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou C, Chen X, Zeng W, Peng C, Huang G,
Li X, Ouyang Z, Luo Y, Xu X, Xu B, et al: Propranolol induced
G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK
pathway. Oncotarget. 7:68314–68327. 2016.PubMed/NCBI
|
|
23
|
Wolter JK, Wolter NE, Blanch A, Partridge
T, Cheng L, Morgenstern DA, Podkowa M, Kaplan DR and Irwin MS:
Anti-tumor activity of the beta-adrenergic receptor antagonist
propranolol in neuroblastoma. Oncotarget. 5:161–172. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Işeri OD, Sahin FI, Terzi YK, Yurtcu E,
Erdem SR and Sarialioglu F: beta-Adrenoreceptor antagonists reduce
cancer cell proliferation, invasion, and migration. Pharm Biol.
52:1374–1381. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Choy C, Raytis JL, Smith DD, Duenas M,
Neman J, Jandial R and Lew MW: Inhibition of β2-adrenergic receptor
reduces triple-negative breast cancer brain metastases: The
potential benefit of perioperative β-blockade. Oncol Rep.
35:3135–3142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Madden KS, Szpunar MJ and Brown EB:
β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by
divergent pathways in high β-AR-expressing breast cancer cell
lines. Breast Cancer Res Treat. 130:747–758. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martin AC, Zhang G, Rueter K, Khoo SK,
Bizzintino J, Hayden CM, Geelhoed GC, Goldblatt J, Laing IA and Le
Souëf PN: Beta2-adrenoceptor polymorphisms predict response to
beta2-agonists in children with acute asthma. J Asthma. 45:383–388.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leineweber K and Heusch G: Beta 1- and
beta 2-Adrenoceptor polymorphisms and cardiovascular diseases. Br J
Pharmacol. 158:61–69. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Frey UH, Kottenberg E, Kamler M,
Leineweber K, Manthey I, Heusch G, Siffert W and Peters J: Genetic
interactions in the β-adrenoceptor/G-protein signal transduction
pathway and survival after coronary artery bypass grafting: A pilot
study. Br J Anaesth. 107:869–878. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wenjuan Y, Yujun L and Ceng Y: Association
of single nucleotide polymorphisms of β2-adrenergic receptor gene
with clinicopathological features of pancreatic carcinoma. Acta
Histochemica. 115:198–203. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang H, Hao B, Chen X, Zhao N, Cheng G,
Jiang Y, Liu Y, Lin C, Tan W, Lu D, et al: Beta-2 adrenergic
receptor gene (ADRB2) polymorphism and risk for lung
adenocarcinoma: A case-control study in a Chinese population.
Cancer Lett. 240:297–305. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lei YY, Wang WJ, Mei JH and Wang CL:
Mitogen-activated protein kinase signal transduction in solid
tumors. Asian Pac J Cancer Prev. 15:8539–8548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Howe LR, Subbaramaiah K, Brown AM and
Dannenberg AJ: Cyclooxygenase-2: A target for the prevention and
treatment of breast cancer. Endocr Relat Cancer. 8:97–114. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chin CC, Li JM, Lee KF, Huang YC, Wang KC,
Lai HC, Cheng CC, Kuo YH and Shi CS: Selective β2-AR blockage
suppresses colorectal cancer growth through regulation of
EGFR-Akt/ERK1/2 signaling, G1-phase arrest, and apoptosis. J Cell
Physiol. 231:459–472. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu X, Wu WK, Yu L, Sung JJ, Srivastava G,
Zhang ST and Cho CH: Epinephrine stimulates esophageal
squamous-cell carcinoma cell proliferation via
beta-adrenoceptor-dependent transactivation of extracellular
signal-regulated kinase/cyclooxygenase-2 pathway. J Cell Biochem.
105:53–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dey M, Brisson J, Davis G, Enever R, Pray
K, Zaim B and Dvornik D: Relationship between plasma propranolol
concentration and dose in young, healthy volunteers. Biopharm Drug
Dispos. 7:103–111. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pasquier E, Street J, Pouchy C, Carre M,
Gifford AJ, Murray J, Norris MD, Trahair T, Andre N and Kavallaris
M: β-blockers increase response to chemotherapy via direct
antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J
Cancer. 108:2485–2494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shakhar G and Ben-Eliyahu S: In vivo
beta-adrenergic stimulation suppresses natural killer activity and
compromises resistance to tumor metastasis in rats. J Immunol.
160:3251–3258. 1998.PubMed/NCBI
|
|
40
|
Zhou L, Li Y, Li X, Chen G, Liang H, Wu Y,
Tong J and Ouyang W: Propranolol attenuates surgical Stress-induced
elevation of the regulatory T cell response in patients undergoing
radical mastectomy. J Immunol. 196:3460–3469. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang XY, Wang HC, Yuan Z, Huang J and
Zheng Q: Norepinephrine stimulates pancreatic cancer cell
proliferation, migration and invasion via β-adrenergic
receptor-dependent activation of P38/MAPK pathway.
Hepatogastroenterology. 59:889–893. 2012.PubMed/NCBI
|
|
42
|
Kim HS, Moon HG, Han W, Yom CK, Kim WH,
Kim JH and Noh DY: COX2 overexpression is a prognostic marker for
Stage III breast cancer. Breast Cancer Res Treat. 132:51–59. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Feigelson HS, Teras LR, Diver WR, Tang W,
Patel AV, Stevens VL, Calle EE, Thun MJ and Bouzyk M: Genetic
variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1,
IRS1, IRS2, and SHC1 and risk for breast cancer in the cancer
prevention study II. Breast Cancer Res. 10:R572008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Radhakrishnan A, Chen YH, Martin S,
Alhusaini N, Green R and Coller J: The DEAD-box protein Dhh1p
couples mRNA decay and translation by monitoring codon optimality.
Cell. 167:122–132.e9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Marson FA, Bertuzzo CS, Ribeiro AF and
Ribeiro JD: Polymorphisms in ADRB2 gene can modulate the response
to bronchodilators and the severity of cystic fibrosis. BMC Pulm
Med. 12:502012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Metra M, Covolo L, Pezzali N, Zacà V,
Bugatti S, Lombardi C, Bettari L, Romeo A, Gelatti U, Giubbini R,
et al: Role of beta-adrenergic receptor gene polymorphisms in the
long-term effects of beta-blockade with carvedilol in patients with
chronic heart failure. Cardiovasc Drugs Ther. 24:49–60. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ahles A, Rochais F, Frambach T, Bünemann M
and Engelhardt S: A polymorphism-specific ‘memory’ mechanism in the
β2-adrenergic receptor. Sci Signal. 4:ra532011.
View Article : Google Scholar : PubMed/NCBI
|
